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Abstract:  Anthrax  is  a  highly  lethal  infectious  disease  caused  by  the  spore-forming 
bacterium Bacillus anthracis. It not only causes natural infection in humans but also poses 
a great threat as an emerging bioterror agent. The lethality of anthrax is primarily attributed 
to the two major virulence factors: toxins and capsule. An extensive effort has been made 
to  generate  therapeutically  useful  monoclonal  antibodies  to  each  of  the  virulence 
components: protective antigen (PA), lethal factor (LF) and edema factor (EF), and the 
capsule of B. anthracis. This review summarizes the current status of anti-anthrax mAb 
development and argues for the potential therapeutic advantage of a cocktail of mAbs that 
recognize different epitopes or different virulence factors. 
Keywords: Bacillus anthracis; anti-PA mAbs; anti-LF mAbs; anti-EF mAbs; anti-capsule 
mAbs; post-exposure treatment of anthrax; a cocktail of mAbs 
 
1. Anthrax Disease and Its Virulence Determinants 
Bacillus anthracis, the causative agent of anthrax, is a Gram-positive, spore-forming bacterium that 
infects mostly herbivores. Humans are occasionally infected when exposed to contaminated animal 
products. However, anthrax poses a great threat as an emerging bioterror agent, highlighted by the 
anthrax attacks in 2001 [1,2]. 
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There  are  three  forms  of  anthrax  disease,  cutaneous,  gastrointestinal  and  inhalational  anthrax, 
depending on the route of infection. Inhalational anthrax is the deadliest form and the form used as a 
biological  weapon  in  2001.  The  high  lethality  of  inhalational  anthrax  is  largely  attributed  to  the 
efficient replication of the bacterium and the action of its toxins. Following inhalation, spores are taken 
up either by alveolar macrophages or pulmonary dendritic cells and transported to local lymph nodes. 
These spores then germinate over the course of 2 to 43 days. Clinical symptoms develop rapidly after 
germination, and coincide with the production of toxins. Actively dividing bacilli produce three toxin 
components: protective antigen (PA), lethal factor (LF) and edema factor (EF). PA binds to cellular 
receptors and acts as a vehicle to deliver LF or EF into the cytosol where they exert their enzymatic 
activities (for review, see van der Goot, G. & Young, J.A. 2009) [3]. LF is a zinc-dependent protease 
that cleaves  mitogen-activated protein kinase kinases  [4,5].  EF is  a calcium-calmodulin-dependent 
adenylate cyclase [6]. The combination of PA with LF results in lethal toxin (LT). LT can replicate 
symptoms of anthrax disease when injected into animals (for review, see Moayeri, M. & Leppla, S.H. 
2009) [7]. PA combines with EF to form edema toxin (ET) which can produce a range of toxic effects 
in the host (for review, see Moayeri, M. & Leppla, S.H. 2009) [7].  
In addition  to  the anthrax toxins  (LT and ET), the vegetative bacillus  also  produces  a capsule 
composed of a polymer of D-glutamic acid linked by γ-peptidyl bonds (γ DPGA). The toxins and the 
capsule  comprise  two  major  virulence  factors  that  are  associated  with  anthrax  pathogenesis.  The 
anthrax toxins play a key role in virulence by suppressing immune cell and cytokine responses, thereby 
promoting bacterial survival at early stages of infection, while inducing the shock-like death associated 
with anthrax at later stages following bacterial outgrowth in the blood [8]. On the other hand, the  
γ DPGA capsule allows bacteria to evade phagocytosis and has been shown to be essential for bacterial 
dissemination in the mouse and primate animal models [9,10]. The genes responsible for producing 
these two virulence factors are carried by two plasmids, pXO1 and pXO2, respectively. The loss of 
either plasmid results in attenuation of virulence [11,12], confirming the essential role of each factor 
for full virulence.  
2. The Limitations of Currently Recommended Post-Exposure Treatment 
Current CDC recommendations following potential exposure to aerosolized B. anthracis spores are 
60 days of oral antibiotics combined with a 3-dose series of the PA-based anthrax vaccine (anthrax 
vaccine adsorbed, AVA, BioThrax) [13]. While antibiotics and vaccination are an integral part of 
medical care, both have limitations. Antibiotics are effective in killing bacteria, but they are unable to 
clear  released  toxins  from  the  bloodstream.  Thus,  unless  exposure  is  diagnosed  early  enough  for 
antibiotic treatment to prevent significant bacterial replication, patients will succumb to toxin-induced 
disease  even  after  the  killing  of  all  bacteria  [1].  In  addition,  there  is  growing  concern  about  the 
possibility that a future bioterror attack could involve antibiotic resistant strains. Mutant strains that are 
resistant to the currently recommended antibiotics doxycycline and ciprofloxacin are rare in nature, but 
such resistant strains could be readily generated using straightforward experimental procedures in the 
laboratory [14,15]. The need for up to 60 days of antibiotic therapy tends to decrease compliance, as 
seen in the treatment associated with the 2001 attacks, for which the adherence rate was estimated to 
be 42% [16,17]. The current PA-based vaccine requires repeated administration and at least 4 weeks Toxins 2011, 3                              
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for  development  of  anti-PA  protective  titers.  Given  the  short  incubation  time  and  rapid  disease 
progression  of  inhalational  anthrax,  vaccination  is  unlikely  to  afford  protection  after  exposure.  
Thus,  there  exists  a  need  for  improved  therapies  to  augment  available  treatment  options  for 
inhalational anthrax. 
3. Passive Immunization through Treatment with mAbs 
Passive immunization with protective antibodies represents  an attractive  option to  augment  the 
current post-exposure treatment of anthrax since it can provide immediate and extensive protection 
that is not dependent on the host response. Indeed, passive immunization with protective antibody has 
been  considered  to  be  the  only  available  countermeasure  in  biodefense  [18].  The  overwhelming 
evidence indicates that antibodies are key players in conferring immunity to anthrax [19–22]. Thus, 
during the past 10 years, extensive research has been focused on development of therapeutic antibodies 
to target anthrax. This review summarizes the current status of therapeutic mAbs directed against the 
major  virulence  factors:  PA,  LF,  EF  and  capsule.  Furthermore,  an  argument  for  the  possible 
therapeutic advantage of a cocktail of several  mAbs  that recognize different  epitopes or different 
virulence factors (PA, LF, EF and capsule) is presented.  
3.1. Current Status of Anti-Anthrax mAb Development  
3.1.1. Anti-PA mAbs 
The central role of PA in the pathophysiology of anthrax makes it an excellent therapeutic target. 
Vaccination with the PA-based human anthrax vaccine [23] or purified PA [24–26] results in the 
generation of a protective immune response. Passive immunization with polyclonal antibodies against 
PA is highly protective against challenge with B. anthracis spores [27–29]. Moreover, antibody titers 
against PA correlate with protective immunity against spore challenge [19–22]. The human polyclonal 
antibodies  (anthrax  immune  globulin,  AIG)  from  plasma  of  human  volunteers  who  have  been 
vaccinated with AVA have been recommended for use as an Emergency Investigational New Drug. 
The  recent  treatment  with  AIG  of  a  patient  who  naturally  acquired  inhalation  anthrax  showed 
beneficial effect [30]. However, mAbs are the preferred choice for immunoprophylaxas as they offer 
several advantages over polyclonal antibodies, including defined specificity, reproducible efficacy, 
unlimited supply, high  purity and increased safety. So far,  greater than ten highly potent anti-PA 
neutralizing  mAbs  have  been  generated  using  different  approaches  [31–40].  These  antibodies 
neutralize PA by different mechanisms, which include (i) inhibition of receptor binding [35–37,40],  
(ii) interference with PA heptamer formation [41], (iii) interference with LF or EF binding to PA [31], 
(iv) blockage of the enzymatic cleavage of PA into PA63 [34], and (v) disruption of preformed PA 
heptamer through formation of a supercomplex [39,42]. Some of the mAbs are murine-derived and are 
not useful in clinical applications because they will elicit detrimental anti-antibody immune responses 
in  humans  unless  “humanized”.  With  the  advent  of  new  antibody  technologies,  it  is  possible  to 
generate fully human or human-like mAbs. Currently, six such clinically useful anti-PA mAbs are 
available (Table 1) and each of them will be discussed below. 
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Table 1. Human and human-like anti-PA neutralizing monoclonal antibodies. 
mAb  Origin 
Epitope 
(Domain) 
Neutralizing Mechanism 
Animal Model for  
in vivo Protection 
Reference 
Abthrax  Human  IV  Inhibition of receptor binding  Rat, rabbit and monkey  [37] 
AVP-21D9  Human  III  Interference with toxin assembly  Rat 
1 and rabbit 
2  [38,43] 
ETI-204  Humanized  IV  Inhibition of receptor binding  Rabbit  [40] 
MDX 1303  Human  III 
Disruption of preformed PA 
heptamer 
Rabbit and monkey 
3  [39] 
IQNPA  Human  IV  Inhibition of receptor binding  Mouse 
4  [35] 
W1  Chimpanzee  IV  Inhibition of receptor binding  Rat and mouse  [36] 
1  Fischer  344  rats  challenged  with  LT; 
2  Rabbits  challenged  with  virulent  B.  anthracis  Ames  spores;  
3  Monkeys  challenged  with  virulent  B.  anthracis  Ames  spores; 
4  A/J  mice  challenged  with  toxigenic 
B. anthracis Sterne spores. 
Abthrax (Raxibacumab) from Human Genome Sciences (HGS) is a fully human mAb derived from 
a human antibody phage display library licensed by HGS from Cambridge Antibody Technology [37]. 
The mAb presumably binds to domain IV of PA with an affinity of 2.78 nM and inhibits the binding of 
PA to its receptor. The in vivo protection was initially demonstrated in a rat toxin-challenge model and 
pre- and post exposure protection was further demonstrated in both New Zealand white rabbits and 
cynomolgus monkeys following lethal challenge of B. anthracis Ames spores. AVP-21D9 from Avanir 
Pharmaceuticals is a fully human mAb that was generated from human peripheral blood lymphocytes 
of AVA-immunized donors. The mAb has very high affinity with a Kd of 0.082 nM and inhibits PA 
heptamer formation [43,44]. The protective efficacy was initially demonstrated in a rat toxin-challenge 
model and pre- and postexposure protection was subsequently confirmed in Dutch-belted dwarf and 
New Zealand white rabbits following lethal challenge with virulent B. anthracis Ames spores [38]. 
ETI-204  (Anthim)  from  Elusys  Therapeutics  is  a  humanized,  affinity-improved  variant  of  mouse 
monoclonal antibody, 14B7 [31]. The mAb binds to domain IV of PA with an affinity of 0.33 nM and 
inhibits PA binding to receptor. Pre- and postexposure protection was demonstrated in New Zealand 
white rabbits following lethal challenge of B. anthracis Ames spores [40]. MDX1303 (Valortin) from 
PharmAthene/Medarex is a fully human mAb that was generated from HuMab transgenic mice that 
were engineered to express human immunoglobulin [45]. The mAb recognizes domain III of PA and 
potentially disrupts preformed PA heptamers by formation of a supercomplex in a manner similar to 
what  was  described  for  related  antibody  1G3  [42].  The  binding  affinity  has  not  been  reported. 
Interestingly, the neutralizing activity of the mAb is dependent on Fc receptor. Pre-exposure protection 
was  demonstrated  in  both  New  Zealand  white  rabbits  and  cynomolgus  monkeys  following  lethal 
challenge with B. anthracis Ames spores [39]. IQNPA from IQ Corporation is a fully human mAb that 
was  developed  from  peripheral  blood  lymphocytes  from  anthrax  vaccine-immunized  donors  using 
electrofusion hybridoma technology. The mAb recognizes domain IV of PA and presumably inhibits 
the binding of PA to its cell receptor. Preexposure protection was determined in A/J mice challenged 
with a lethal dose of unencapsulated toxigenic Sterne strain [35]. W1 from the National Institute of 
Allergy  and  Infectious  Diseases  is  a  chimpanzee/human  chimeric  mAb  that  was  recovered  from 
chimpanzees immunized with PA by phage display library technology. W1 has the highest affinity 
among neutralizing antibodies which interact with the receptor-binding domain IV of PA, with Kd of Toxins 2011, 3                              
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0.04 nM. W1 demonstrated high protective potency in rats using toxin bolus and infusion challenge 
models as well as in A/J mice challenged with a lethal dose of B. anthracis Sterne spores [36,46]. 
Currently,  HGS  has  completed  safety  studies  of  Abtrhax  in  humans  [47]  and  was  awarded  a 
contract to provide a stockpile of 65,000 doses for treatment of inhalation anthrax. Elusys Therapeutics 
has completed a Phase 1 clinical study with ETI204 and the drug has received Fast-Track and Orphan 
Drug status by the FDA. Similarly, a Phase 1 clinical trial with mAb MDX1303 has been completed 
and  the  mAb  has  also  received  Fast-Track  and  Orphan  Drug  status  by  the  FDA.  Since  different 
neutralizing  mechanisms  are  used  by  these  mAbs  and  different  animal  models,  challenge  doses, 
antibody doses, and routes of administration have been used in their testing, it is difficult to directly 
compare these anti-PA mAbs. Furthermore, limited resources and high costs of testing have delayed 
the testing of some mAbs in the preferred rabbit or monkey inhalational anthrax models. However, it 
has been shown that affinity correlates well with neutralizing activity; higher affinity conferred better 
protection for mAbs that are specific to domain IV of PA [36,48]. Since mAbs that are specific to 
domain IV of PA neutralize by inhibiting the binding of PA to its receptor, it is essential that mAbs 
bind to PA with higher affinity than the interaction between PA and its receptor. A range of affinities 
for PA and its receptors has been reported, from 0.17 to 33.3 nM [49–52]. To compete effectively with 
the PA receptor for PA binding, mAbs need to have an affinity greater than this range. Comparison 
among four mAbs that neutralize PA by inhibiting the binding of PA to its receptor indicates that the 
only  mAb  that  truly  falls  outside  the  range  of  affinities  for  PA  and  its  receptor  is  anti-PA  W1  
(Table 2). However, the efficacy of W1 relative to other antibodies has not been assessed in the rabbit 
or non-human primate models.  
Table  2.  Comparison  of  human  or  human-like  mAbs  that  recognize  the  same  
receptor-binding domain of PA. 
mAb  Affinity (Kd)  Antibody dose for 100% protection  Reference 
Abthrax  2.78 nM  1.5 mg/kg in rat 
2, 40 mg/kg in rabbit 
3, 40 mg/kg in monkey 
4  [37] 
ETI-204  0.33 nM  4 mg/kg in rabbit 
3  [40] 
IQNPA  ND 
1  7.2 mg/kg in mouse 
5  [35] 
W1  0.04 nM  0.021 mg/kg in rat 
2, 1.6 mg/kg in mouse 
6  [36] 
1 ND: not determined; 
2 Fischer 344 rats were challenged with LT; 
3 New Zealand white rabbit 
inhalational anthrax model with B. anthracis Ames spores; 
4 Cynomolgus macaque inhalational 
anthrax model challenged with B. anthracis Ames spores. 90% protection at the dose indicated;  
5  A/J  mice  were  challenged  with  24  LD50  of  B.  anthracis  Sterne  spores; 
6  Unpublished  data.  
A/J mice were challenged with 2 ×  10
7 Stern spores (~1000 LD50). All PBS-treated mice died 48 h 
after challenge. 
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3.1.2. Anti-LF mAbs 
LF  plays  a  pivotal  role  in  cytotoxicity  and  progression  of  disease  in  the  infected  host  [53]. 
Currently, several neutralizing mAbs specific to LF have been reported. Some of the well-characterized 
anti-LF mAbs are listed in Table 3. Most of them are murine-derived and are not suitable for use in 
humans, and therefore, will not be discussed further. IQNLF is a fully human mAb, while LF10E and 
LF11H are chimpanzee/human chimeric mAbs. IQNLF recognizes domain I of LF and thus likely 
inhibits the binding of LF to PA which occurs through this domain. A single dose of 180 µg of IQNLF 
conferred 100% protection to A/J mice that were challenged with 24 LD50 of B. anthracis Sterne 
spores [35]. MAbs LF10E and LF11H bind to domain I of LF with affinities of 0.69 nM and 7.4 nM, 
respectively. Interestingly, neither mAb inhibits the binding of LF to PA. Initial experiments showed 
that LF10E and LF11H at substoichiometric or equal molar ratios of 1:0.5 and 1:1 of LF to mAb, 
respectively,  conferred  100%  protection  of  Fischer  344  rats  from  challenge  with  LT  [54].  
A recent experiment showed that 200 µg of LF10E provided 100% protection of A/J mice challenged 
with 1000 LD50 of B. anthracis Sterne spores (data not shown).  
Table 3. Characteristics of available anti-LF neutralizing mAbs. 
mAb  Origin 
Affinity 
(Kd) 
Epitope 
(Domain) 
In vitro Neutralization 
(EC50) 
In vivo Neutralization  Reference 
LF8  Mouse  ND 
1  I  + (ND) 
3  Athymic nude mouse 
4  [55] 
9A11  Mouse  70.1 nM  ND  1.3 nM  Balb/C mouse 
5  [33] 
10G3  Mouse  20 nM 
2  I  + (ND)  Fischer 344 rat  [56] 
2E7  Mouse  87 nM 
2  I  + (ND)  Fischer 344 rat  [56] 
3F6  Mouse  40 nM 
2  I  + (ND)  Fischer 344 rat  [56] 
5B13B1  Mouse  2.62 nM  III  1.4 nM  Fischer 344 rat  [57] 
3C16C3  Mouse  8.18 nM  III  4.2 nM  Fischer 344 rat  [57] 
IQNLF  Human  ND  I  0.1 nM  A/J mouse  [35] 
LF10E  Chimpanzee  0.69 nM  I  0.1 nM 
Fischer 344 rat and A/J 
mouse 
[54] 
LF11H  Chimpanzee  7.4 nM  I  400 nM  Fischer 344 rat  [54] 
1 ND: not determined; 
2 Calculated IgG concentration for 50% maximal binding in ELISA based on original 
data; 
3 Positive in in vitro neutralization assay, but EC50 was not determined; 
4 MAb and LT were injected 
intravenously  into  athymic  nude  (nu/nu)  mice  daily; 
5  Balb/C  mice  were  injected  with  mAb  and  then 
challenged with LT intraperitoneally. 
3.1.3. Anti-EF mAbs 
Fewer  neutralizing mAbs  to  EF have been  reported as  compared to  mAbs against PA and  LF 
(Table 4) [58–60]. This is perhaps because EF has been considered to contribute less to the lethality of 
anthrax  infection  [61,62]  and  epitopes  in  EF  that  elicit  nonneutralizing  mAbs  appear  to  be 
immunodominant as most mAbs to EF reported thus far do not neutralize EF [58–60]. Nevertheless, 
one of the EF-neutralizing mAbs,  EF13D is  very promising for therapeutic use  [59]. EF13D is  a 
chimpanzee/human mAb that can neutralize EF in vitro in the subnanomolar range. The therapeutic 
usefulness of the antibody was demonstrated by its efficient prevention of local edema formation in a Toxins 2011, 3                              
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murine footpad model, as well as protection of mice from death following edema toxin challenge. 
EF13D binds to a conformational epitope within domain III of EF with very high affinity (Kd of  
0.05–0.12 nM). The antibody can not only inhibit the binding of calmodulin (CaM) (which is required 
for activity) to EF, but also can displace pre-bound CaM from the EF-CaM complex. 
Table 4. Characteristics of anti-EF neutralizing mAbs. 
mAb  Origin  Affinity (Kd) 
1  In Vitro Neutralization 
2  In Vivo Neutralization 
3  Reference 
9F5  Mouse  2 nM  Yes  ND  [58] 
1E6  Mouse  5 nM  Yes  ND  [58] 
7G10  Mouse  9 nM  Yes  ND  [58] 
9F3  Mouse  830 nM  Yes  No  [60] 
EF13D  Chimpanzee  0.05–0.12 nM  Yes  Yes  [59] 
1 The affinities for mAbs 1E6, 7G10, 9F5 and 9F3 were estimated from binding assay by ELISA and affinity 
for mAb EF13D was determined by surface plasmon resonance on Biacore; 
2 The in vitro neutralization 
activity was measured by the ability of antibody to inhibit cyclase activity of EF; 
3 In vivo neutralization 
assay was not determined for mAbs 1E6, 7G10 and 9F5 (ND). Prolonged but, ultimately no survival of A/J 
mice treated with mAb 9F3 was observed following challenge with Sterne spores. MAb EF13D prevented 
local edema formation and protected mice from death following challenge with ET. 
3.1.4. Anti-Capsule mAbs 
The capsule is poorly immunogenic and acts as a thymus-independent, type 2 antigen [63]. Due to 
the lack of effective antibody response to the capsule, the antiphagocytic nature of the capsule ensures 
the  unchecked  proliferation  of  bacilli.  Clearly,  the  current  PA-based  vaccine  would  not  elicit  the 
production of anti-capsule antibodies and therefore, such antibodies are absent from AIG currently 
stocked for use as an Emergency Investigational New Drug. The inherently weak immunogenicity of 
the  capsule  can  be  significantly  enhanced  through  conjugation  to  a  strong  immunogenic  protein 
carrier [64–67] or by administration of γDPGA in combination with a CD40 agonist mAb [68]. By 
these  approaches,  several  murine  and  chimpanzee-derived  mAbs  that  promote  effective 
oposonophagocytosis of B. anthracis have been isolated (Table 5) [68–70]. Passive immunization with 
these specific anti-capsule mAbs conferred significant protection in naï ve mice against spores of the 
Ames strain. In comparison, the chimpanzee-derived anti-capsule mAbs 11D and 4C had an order of 
magnitude higher binding affinities  and conferred better protection than murine mAbs  [70]. More 
importantly, 11D and 4C not only provided pre-exposure protection, but also protection against lethal 
infection when mAbs were administrated as late as 20 h after spore challenge. These mAbs could be 
particularly useful for treatment of infections with antibiotic-resistant strains. 
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Table 5. Comparison of some well characterized anti-capsule neutralizing mAbs. 
mAb  Origin  Affinity (Kd) 
1  Antibody Dose for 100% Protection 
2  Reference 
F26G3  Mouse  370 nM  2–4 mg  [69] 
F24F  Mouse  500 nM  2 mg  [69] 
F26G4  Mouse  510 nM  2–4 mg  [69] 
4C  Chimpanzee  36 nM  0.3 mg  [70] 
11D  Chimpanzee  64 nM  0.3–1 mg  [70] 
1 The  Kd was  determined  by  fluorescence  tryptophan  perturbation  assay; 
2  Murine  model  of  pulmonary 
anthrax: Balb/c mice were challenged with lethal infection of Ames spores.  
3.2. Maximizing the Efficacy of Antibody Therapy by Targeting Multiple Epitopes 
Even though a single mAb that neutralizes one of the anthrax virulence components (PA, LF, EF 
and capsule), particularly PA, may be sufficient to confer significant protection, a mixture of more 
than  one  mAb  against  different  targets  or  epitopes  could  maximize  the  protective  efficacy.  Such 
combinatorial  therapy  would  not  only broaden the spectrum  of protection but  may  also  synergize 
protective  efficacy.  The  synergistic  effect  of  multiple  mAbs  has  been  well  documented  in  other 
diseases. A dramatic synergistic effect has been reported for mAbs to botulinum neurotoxin type A 
(BoNT/A)  [71].  A  mixture  of  three  anti-BoNT/A  mAbs  increased  protective  efficacy  by  at  least  
1000-fold when compared with individual mAbs used alone. A similar effect has been observed for 
anti-tetanus mAbs, where a combination of two mAbs provided complete protection against a lethal 
tetanus  toxin  challenge  in  mice,  while  single  mAbs  were  not  protective  [72].  The  benefit  of  
mAb  combinations  in  the  neutralization  of  Rift  Valley  fever,  HIV  and  dengue  viruses  has  also  
been reported [73–76].  
For anthrax, several anti-PA mAbs that recognize different epitopes and thereby employ different 
neutralization mechanisms have been generated. Each mAb, regardless of differences in neutralizing 
mechanism, demonstrated highly potent neutralizing activity [31–40]. However, a point mutation in 
the  neutralization  epitope  introduced  naturally  or  intentionally  can  abolish  antibody  activity  as 
demonstrated by the involvement of a single amino acid as crucial to neutralizing antibody function in 
the  PA-antibody  interaction  [77].  Obviously,  a  cocktail  of  anti-PA  mAbs  that  recognize  different 
epitopes on PA would broaden the spectrum of protection, which would be much more difficult to 
overcome by escape mutants since multiple point mutations in different epitopes essential to toxin 
function would be necessary for escape. Furthermore, it is possible that such a combination of different 
anti-PA mAbs with different specificities would synergize the protective efficacy.  
Synergy between anti-PA and anti-LF antibodies has also been investigated. The efficacy of three 
mouse mAbs recognizing domain 2 and domain 4 of PA and the N-terminus of LF, were tested in a 
mouse Sterne spore-challenge model, in combination and alone [34]. A combination of 1 µg of each 
mAb resulted in full protection while individual mAbs at doses of 1 µg or 10 µg conferred 0–25% 
protection. Synergy between anti-PA and anti-LF was also observed in a rat LT-challenge model with 
anti-PA W1 and anti-LF LF11H [54]. These results are consistent with the notion that although PA 
plays the central role in protective immunity antibodies against LF and EF can also play an important 
role in protection [78–80].  Toxins 2011, 3                              
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Anthrax  is  a  complex  disease  involving  several  steps  to  establish  infection,  including  spore 
germination, proliferation of bacilli and toxin production, leading to bacteremia and toxemia. Ideally, 
mAbs to each of the virulence factors could be used together, so that a comprehensive protection could 
be achieved by inhibiting multiple steps of infection (Figure 1). The finding that PA is present on the 
surface of the dormant spore and that antibodies to PA enhance spore phagocytosis and spore killing 
by macrophages in vitro [81–83] suggests that anti-PA mAbs may interfere with the early stage of 
infection.  Furthermore,  it  has  recently  be  shown  that  toxin  function  against  macrophages  and 
neutrophils  is  essential  to  avoiding  bacterial  clearance  by  these  immune  cells  and  establishing 
infection, confirming an important role for anti-toxin antibodies in early stages [53]. In addition to 
anti-toxin antibodies interfering with early steps in infection, the actively dividing vegetative bacteria 
can be killed by anti-capsule mAbs through opsonophagocytosis. High levels of toxin synthesized later  
in  infection  and  responsible  for  lethality  in  this  disease  can  also  be  neutralized  by  anti-PA,  -LF  
and -EF mAbs.  
Figure  1.  Comprehensive  protection  could  be  achieved  by  a  combination  of  anti-PA,  
anti-LF, anti-EF and anti-PGA mAbs that target major steps of the infection process.  
 
At  the  very  least,  the  combination  of  anti-PA  and  anti-capsule  mAbs  may  be  sufficient  for 
maximum efficacy since they combine both anti-bacterial and anti-toxin activities. Even though anti-PA 
mAb alone is very effective in protection, a greater therapeutic efficacy has been achieved by passive 
immunity from anti-PA mAbs in combination with antibiotics [41,84]. Thus, it is reasonable to assume 
that the same effect could be achieved by combination of anti-PA and anti-capsule mAbs. Actually, 
anti-capsule mAbs compare favorably with antibiotics in terms of treating antibiotic-resistance strains 
and providing a prolonged duration of protection. It is critically important that we are prepared to treat 
anthrax infection that involves antibiotic-resistant strains since such strains could be readily generated 
in  the  laboratory  as  described  above.  Anti-capsule  mAb  is  a  clear  choice  for  treating  such  
antibiotic-resistance strains. Human IgG1 has a considerably longer serum half-life than antibiotics (21 
days vs. 0.1–0.2 day), and this extended duration of efficacy can be quite dramatic. For example, most 
antibiotics have to be taken once or more daily, but a single dose of an antibody may protect for more 
than 20 days. The duration of protection is especially important in anthrax treatment because anthrax 
spores can remain dormant in the lungs for an extended period of time [85–86] and a 60-day course of Toxins 2011, 3                              
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oral antibiotics is recommended, which has resulted in poor compliance [16,17]. By contrast, due to its 
longer half-life, 2–3 doses of mAbs may be sufficient to provide protection for more than 60 days.  
4. Conclusions  
Several  therapeutically  useful  anti-PA,  anti-LF,  anti-EF  and  anti-capsule  mAbs  have  been 
generated. These mAbs used alone would most likely improve currently recommended post-exposure 
treatment of anthrax. Use of a cocktail of mAbs that target different epitopes or virulence factors could 
maximize the protective efficacy as it would not only broaden the spectrum of protection but may also 
synergize the protective efficacy. In particular, therapy that included an anti-capsule mAb could be 
useful for treatment of infections with antibiotic-resistant strains.  
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